Cardiometabolic & kidneySecondary analysis
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c
- Pooled secondary analysis of the SCORED and SOLOIST-WHF randomised trials
- subgroup analysis by baseline HbA1c
Authors' conclusion
In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c.
Study context
- Population
- Adults with T2DM and heart failure (HF) or kidney disease, by baseline HbA1c (≤7.5%, 7.6% to 9.0%, >9.0%)
- Participants
- 11,744 adults
- Comparison
- Sotagliflozin vs placebo
- Primary endpoint
- Composite of:
- CV death
- HF hospitalizations
- Urgent HF visits
Primary result
As reported in the abstract
Primary outcome by baseline HbA1c
Sotagliflozin vs PlaceboHazard ratio (95% CI)
HbA1c ≤7.5%: 11.2 vs 15.5 per 100 person-years
0.73(0.57–0.93)
HbA1c 7.6% to 9.0%: 7.3 vs 9.4 per 100 person-years
0.77(0.63–0.96)
HbA1c >9.0%: 7.8 vs 11.6 per 100 person-years
0.65(0.50–0.84)
Original publication
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c. J Am Coll Cardiol. Published 7 November 2023. doi:10.1016/j.jacc.2023.08.050
Summarised from the published abstract; every number is checked against it